The latest price target for Kymera Therapeutics (NASDAQ:KYMR) was reported by Stephens & Co. on January 21, 2025. The analyst firm set a price target for $60.00 expecting KYMR to rise to within 12 months (a possible 37.30% upside). 27 analyst firms have reported ratings in the last year.

The latest analyst rating for Kymera Therapeutics (NASDAQ:KYMR) was provided by Stephens & Co., and Kymera Therapeutics reiterated their overweight rating.

The last upgrade for Kymera Therapeutics Inc happened on December 2, 2024 when Wells Fargo raised their price target to $57. Wells Fargo previously had an equal-weight for Kymera Therapeutics Inc.

The last downgrade for Kymera Therapeutics Inc happened on January 3, 2024 when B of A Securities changed their price target from $45 to $30 for Kymera Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kymera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kymera Therapeutics was filed on January 21, 2025 so you should expect the next rating to be made available sometime around January 21, 2026.

While ratings are subjective and will change, the latest Kymera Therapeutics (KYMR) rating was a reiterated with a price target of $60.00 to $60.00. The current price Kymera Therapeutics (KYMR) is trading at is $43.70, which is out of the analyst’s predicted range.